{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T09:38:42Z","timestamp":1792834722876,"version":"4.5.0"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"35","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,28]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Patients with psychiatric disorders often have various physical diseases that may be associated with an increase in the number of prescribed drugs. Although clinical guidelines addressing antipsychotic polypharmacy are well established, there is limited evidence of non-psychotropic polypharmacy. To elucidate the actual state of inappropriate polypharmacy, this study examined the number and classes of prescribed medicines stratified by age and comorbidities in patients with psychiatric disorders. This cross-sectional study included patients treated in the psychiatric ward of the National Kohnodai Medical Center from April 2015 to March 2016. The study participants included 250 hospitalized patients (150 in the schizophrenia group, 24 in the bipolar affective disorder group, 18 in the depressive disorders group, and others). We examined the number and classes of psychotropic and non-psychotropic drugs stratified by age and the number of comorbidities. Antipsychotics accounted for 47.8% of all the psychotropic medications. Of the total non-psychotropic drugs, 50.2% were used for the treatment of digestive disorders. Age and number of comorbidities were significantly associated with polypharmacy (defined as a prescription with 5 or more drugs) in patients with psychiatric disorders according to logistic regression analysis (odds ratio\u2005=\u20051.66, 95% confidence interval: 1.39\u20131.97,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.001 for age; odds ratio\u2005=\u20052.04, 95% confidence interval: 1.58\u20132.63,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.001 for comorbidities). Mean non-psychotropic prescription counts rose with both age (0.83 at 10\u201319, 2.18 at 40\u201349, 5.80 at &gt;80 years) and comorbidities (0.84 with 0, 3.63 with 3, 6.57 with &gt;5 comorbidities). The mean number of non-psychotropics per patient was linearly related to age range and the number of comorbidities (linear regression coefficient [\n                      <jats:italic toggle=\"yes\">b<\/jats:italic>\n                      ]\u2005=\u20050.65,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.0009;\n                      <jats:italic toggle=\"yes\">b<\/jats:italic>\n                      \u2005=\u20050.91,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.0002, respectively). However, the mean number of psychotropic medications was not related to age or the number of comorbidities. Similar relationships have been observed in patients with schizophrenia. This study highlights the need to monitor non-psychotropic medications to reduce inappropriate polypharmacy among elderly and multimorbid patients with psychiatric disorders.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050432","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T02:00:35Z","timestamp":1787968835000},"page":"e50432","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Patterns of non-psychotropic medication use and polypharmacy in patients with psychiatric disorders"],"prefix":"10.1097","volume":"105","author":[{"given":"Yoriyasu","family":"Uju","sequence":"first","affiliation":[{"name":"Department of Psychiatry, National Kohnodai Medical Center, Japan Institute for Health Security, Ichikawa City, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6561-3420","authenticated-orcid":false,"given":"Tetsuto","family":"Kanzaki","sequence":"additional","affiliation":[{"name":"Department of Drug Informatics, Graduate School and Faculty of Pharmaceutical Sciences, Chiba University, Chiba City, Japan"},{"name":"Department of Internal Medicine, Sanai Memorial Hospital, Chiba City, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riho","family":"Hosoi","sequence":"additional","affiliation":[{"name":"Department of Drug Informatics, Graduate School and Faculty of Pharmaceutical Sciences, Chiba University, Chiba City, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seisuke","family":"Mimori","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Faculty of Pharmacy, Chiba Institute of Science, Choshi City, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Takizawa","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Faculty of Pharmacy, Chiba Institute of Science, Choshi City, Chiba, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuro","family":"Hayakawa","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, National Kohnodai Medical Center, Japan Institute for Health Security, Ichikawa City, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261024","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.ahj.2005.02.007","article-title":"Schizophrenia and increased risks of cardiovascular disease.","volume":"150","author":"Hennekens","year":"2005","journal-title":"Am Heart J"},{"key":"R2-20261024","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2215-0366(17)30078-0","article-title":"Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis.","volume":"4","author":"Hjorthoj","year":"2017","journal-title":"Lancet Psychiatry"},{"key":"R3-20261024","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.schres.2022.10.019","article-title":"Factors and their weight in reducing life expectancy in schizophrenia.","volume":"250","author":"Correll","year":"2022","journal-title":"Schizophr Res"},{"key":"R4-20261024","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1192\/bjpo.bp.117.004937","article-title":"Premature deaths among individuals with severe mental illness after discharge from long-term hospitalisation in Japan: a naturalistic observation during a 24-year period.","volume":"3","author":"Kondo","year":"2017","journal-title":"BJPsych Open"},{"key":"R5-20261024","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.3390\/ijerph20054336","article-title":"Physical, psychiatric, and social comorbidities of individuals with schizophrenia living in the community in Japan.","volume":"20","author":"Matsunaga","year":"2023","journal-title":"Int J Environ Res Public Health"},{"key":"R6-20261024","first-page":"14","article-title":"Appropriate monitoring may affect the life expectancy of patients with mental disorders in Japan: literature review on guidelines for serious physical risks.","volume":"1","author":"Yasui-Furukori","year":"2022","journal-title":"Dokkyo Med J"},{"key":"R7-20261024","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/schbul\/sbr148","article-title":"Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders\u2013a systematic review and meta-analysis.","volume":"39","author":"Mitchell","year":"2013","journal-title":"Schizophr Bull"},{"key":"R8-20261024","doi-asserted-by":"crossref","first-page":"390","DOI":"10.4239\/wjd.v8.i8.390","article-title":"Prevalence of obesity and diabetes in patients with schizophrenia.","volume":"8","author":"Annamalai","year":"2017","journal-title":"World J Diabetes"},{"key":"R9-20261024","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.schres.2018.03.016","article-title":"Dietary patterns and physical activity in people with schizophrenia and increased waist circumference.","volume":"199","author":"Jakobsen","year":"2018","journal-title":"Schizophr Res"},{"key":"R11-20261024","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12877-017-0621-2","article-title":"What is polypharmacy? A systematic review of definitions.","volume":"17","author":"Masnoon","year":"2017","journal-title":"BMC Geriatr"},{"key":"R12-20261024","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/JCP.0000000000001416","article-title":"Antipsychotic polypharmacy is associated with adverse drug events in psychiatric inpatients: the Japan Adverse Drug Events Study.","volume":"41","author":"Ayani","year":"2021","journal-title":"J Clin Psychopharmacol"},{"key":"R13-20261024","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12888-019-2056-0","article-title":"Polypharmacy in a hospitalized psychiatric population: risk estimation and damage quantification.","volume":"19","author":"Carmona-Huerta","year":"2019","journal-title":"BMC Psychiatry"},{"key":"R14-20261024","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jamapsychiatry.2018.4320","article-title":"Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia.","volume":"76","author":"Tiihonen","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"R15-20261024","doi-asserted-by":"crossref","first-page":"1080073","DOI":"10.3389\/fphar.2023.1080073","article-title":"Psychiatric and non-psychiatric polypharmacy among older adults with schizophrenia: trends from a population-based study between 2000 and 2016.","volume":"14","author":"Lunghi","year":"2023","journal-title":"Front Pharmacol"},{"key":"R16-20261024","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2174\/1389200023338017","article-title":"Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update.","volume":"3","author":"Hemeryck","year":"2002","journal-title":"Curr Drug Metab"},{"key":"R17-20261024","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1176\/appi.ajp.158.11.1774","article-title":"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.","volume":"158","author":"Glassman","year":"2001","journal-title":"Am J Psychiatry"},{"key":"R18-20261024","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMra041867","article-title":"The serotonin syndrome.","volume":"352","author":"Boyer","year":"2005","journal-title":"N Engl J Med"},{"key":"R19-20261024","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa0806994","article-title":"Atypical antipsychotic drugs and the risk of sudden cardiac death.","volume":"360","author":"Ray","year":"2009","journal-title":"N Engl J Med"},{"key":"R20-20261024","doi-asserted-by":"crossref","first-page":"108842","DOI":"10.1016\/j.diabres.2021.108842","article-title":"Polypharmacy difference between older people with and without diabetes: evidence from the English Longitudinal Study of Ageing.","volume":"176","author":"Huang","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"key":"R21-20261024","doi-asserted-by":"crossref","first-page":"436","DOI":"10.3390\/medicina55080436","article-title":"Polypharmacy in type 2 diabetes mellitus: insights from an internal medicine department.","volume":"55","author":"Dobrica","year":"2019","journal-title":"Medicina (Kaunas)"},{"key":"R22-20261024","doi-asserted-by":"crossref","first-page":"294","DOI":"10.35772\/ghm.2023.01059","article-title":"An age-stratified cross-sectional study of antidiabetic and non-antidiabetic drugs prescribed to Japanese outpatients with diabetes.","volume":"5","author":"Kuribayashi","year":"2023","journal-title":"Glob Health Med"},{"key":"R25-20261024","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/15622970510030090","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: acute treatment of schizophrenia.","volume":"6","author":"Falkai","year":"2005","journal-title":"World J Biol Psychiatry"},{"key":"R26-20261024","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3109\/15622975.2012.696143","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance.","volume":"13","author":"Hasan","year":"2012","journal-title":"World J Biol Psychiatry"},{"key":"R28-20261024","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1111\/bcp.14685","article-title":"Trends in polypharmacy and potentially inappropriate medication (PIM) in older and middle-aged people treated for diabetes.","volume":"87","author":"Oktora","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"R29-20261024","first-page":"226","article-title":"ATC\/DDD classification (temporary).","volume":"33","year":"2019","journal-title":"WHO Drug Info"},{"key":"R30-20261024","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","article-title":"The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2019).","volume":"42","author":"Umemura","year":"2019","journal-title":"Hypertens Res"},{"key":"R31-20261024","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s13340-020-00439-5","article-title":"Japanese clinical practice guideline for diabetes 2019.","volume":"11","author":"Araki","year":"2020","journal-title":"Diabetol Int"},{"key":"R32-20261024","doi-asserted-by":"crossref","first-page":"846","DOI":"10.5551\/jat.GL2017","article-title":"Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017.","volume":"25","author":"Kinoshita","year":"2018","journal-title":"J Atheroscler Thromb"},{"key":"R33-20261024","first-page":"218","article-title":"Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth.","volume":"20","author":"Pringsheim","year":"2011","journal-title":"J Can Acad Child Adolesc Psychiatry"},{"key":"R34-20261024","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.2147\/NDT.S456163","article-title":"On the road to individualizing pharmacotherapy for adolescents and adults with schizophrenia - results from an expert consensus following the Delphi method.","volume":"20","author":"Guinart","year":"2024","journal-title":"Neuropsychiatr Dis Treat"},{"key":"R36-20261024","doi-asserted-by":"crossref","first-page":"e0166429","DOI":"10.1371\/journal.pone.0166429","article-title":"High prevalence of obesity, hypertension, hyperlipidemia, and diabetes mellitus in Japanese outpatients with schizophrenia: a nationwide survey.","volume":"11","author":"Sugai","year":"2016","journal-title":"PLoS One"},{"key":"R37-20261024","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s40263-021-00859-0","article-title":"Antipsychotic-induced constipation: a review of the pathogenesis, clinical diagnosis, and treatment.","volume":"35","author":"Xu","year":"2021","journal-title":"CNS Drugs"},{"key":"R38-20261024","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3390\/ijms17060863","article-title":"Prevalence and predictors of clozapine-associated constipation: a systematic review and meta-analysis.","volume":"17","author":"Shirazi","year":"2016","journal-title":"Int J Mol Sci"},{"key":"R39-20261024","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/schbul\/sbr026","article-title":"Divergent trajectories of physical, cognitive, and psychosocial aging in schizophrenia.","volume":"37","author":"Jeste","year":"2011","journal-title":"Schizophr Bull"},{"key":"R40-20261024","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.schres.2008.12.008","article-title":"Physical and mental health-related quality of life among older people with schizophrenia.","volume":"108","author":"Folsom","year":"2009","journal-title":"Schizophr Res"},{"key":"R41-20261024","doi-asserted-by":"crossref","first-page":"4","DOI":"10.15256\/joc.2016.6.72","article-title":"Multimorbidity: what do we know? What should we do?","volume":"6","author":"Navickas","year":"2016","journal-title":"J Comorb"},{"key":"R42-20261024","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/epirev\/mxs009","article-title":"Multimorbidity in older adults.","volume":"35","author":"Salive","year":"2013","journal-title":"Epidemiol Rev"},{"key":"R43-20261024","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1017\/S1041610220003403","article-title":"Frailty in geriatric psychiatry inpatients: a retrospective cohort study.","volume":"34","author":"Aprahamian","year":"2022","journal-title":"Int Psychogeriatr"},{"key":"R44-20261024","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S2215-0366(25)00278-0","article-title":"Antipsychotics for older adults with schizophrenia.","volume":"12","author":"Tampi","year":"2025","journal-title":"Lancet Psychiatry"},{"key":"R45-20261024","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/schbul\/sbac041","article-title":"Maintenance treatment with antipsychotic drugs in schizophrenia: a Cochrane systematic review and meta-analysis.","volume":"48","author":"Ceraso","year":"2022","journal-title":"Schizophr Bull"},{"key":"R46-20261024","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.schres.2016.01.016","article-title":"Difference in prevalence of metabolic syndrome between Japanese outpatients and inpatients with schizophrenia: a nationwide survey.","volume":"171","author":"Sugai","year":"2016","journal-title":"Schizophr Res"},{"key":"R47-20261024","doi-asserted-by":"crossref","first-page":"178","DOI":"10.35772\/ghm.2020.01008","article-title":"Metabolic changes of Japanese schizophrenic patients transferred from hospitalization to outpatients.","volume":"2","author":"Uju","year":"2020","journal-title":"Glob Health Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050432","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T09:00:59Z","timestamp":1792832459000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050432"}},"subtitle":["A cross-sectional study on the association with age and physical comorbidity"],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":42,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050432","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"assertion":[{"value":"2026-03-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}